Dapagliflozin; Dapagliflozin placebo
A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02725593/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 10–24 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 72 чел. во всех странах исследования.
- Плановая дата окончания (04.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 6 · невключение: 19
Критерии включения
- Provision of informed consent prior to any study-specific procedures
- Males and Females, ages 10 years of age, up to but not including 25 years of age at the time of randomization
- Previously diagnosed as having type 2 diabetes for at least 2 months by WHO/ADA diagnostic criteria
- HbA1c >= 6.5% and <= 11% obtained at screening visit
- Currently on diet and exercise and a stable dose of metformin (at least 1000 mg daily) for a minimum of 8 weeks, or stable dose of insulin for a minimum of 8 weeks, or a stable combination of metformin (at least 1000 mg daily) and insulin for a minimum of 8 weeks prior to screening
- FPG <=255 mg/dL (<= 14.2 mmol/L) obtained at screening visit
Критерии невключения
- Previous diagnosis of Type 1 diabetes
- Diabetes ketoacidosis (DKA) within 6 months of screening
- Current use of the following medications for the treatment of diabetes, or use within the specified timeframe prior to screening for the main study:
- Eight weeks: sulfonylureas, alpha glucosidase inhibitors, metiglinide, or injectable incretins or incretin mimetics or other antidiabetes medications not otherwise specified
- Sixteen weeks: thiazolidinediones
- Any previous history or current use of an SGLT2 inhibitor, including dapagliflozin
- Initiation or discontinuation of prescription or non-prescription weight loss drugs within 8 weeks of screening.
- Use of prescription or non-prescription weight loss drugs must be stable during the study
- Pregnant, positive serum pregnancy test, planning to become pregnant during the clinical trials, or breastfeeding
- History of unstable or rapidly progressive renal disease
- History of unresolved vesico-ureteral reflux
- Replacement or chronic systemic corticosteroid therapy, defined as any dose of systemic corticosteroid taken for > 4 weeks within 3 months prior to the Day 1 visit.
- Note: Topical, nasal, or inhaled corticosteroids are allowed
- Abnormal renal function, which is defined in subjects < 18 years of age as an estimated glomerular filtration rate (eGFR) calculated by the Schwartz Formula < 80 mL/min/1.73 m2 (1.33 mL/s), and in subjects >= 18 years as an estimated glomerular filtration rate (eGFR) calculated by the MDRD Formula < 60 mL/min/1.73 m2 (1.33 mL/s)
- Presence of either: antibodies to glutamic acid decarboxylase (GAD) or protein tyrosine phosphatase-like protein antibodies (IA-2)
- An abnormal TSH value at screening will be further evaluated for free T4. Subjects with abnormal free T4 values will be excluded
- Hematuria (confirmed by microscopy at screening) with no explanation as judged by the investigator up to randomization
- Anemia of any etiology defined as hemoglobin <=10.7 g/dL (107 g/L) for females and <= 11.3 g/dL (113 g/L) for males. Subjects who are considered to have anemia according to local guidelines should be excluded
- Volume-depleted subjects. Subjects at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics, should carefully monitor their volume status
Источник: ClinicalTrials.gov, NCT02725593 · запись обновлена в реестре 23 февраля 2022.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24 — Baseline to Week 24
Цель исследования
A trial of patients aged 10-24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety between dapagliflozin and Placebo.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02725593 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.